Fintel reports that on September 27, 2024, Leerink Partners downgraded their outlook for Agios Pharmaceuticals (NasdaqGS:AGIO ...

Investors in Agios Pharmaceuticals, Inc. AGIO need to pay close attention to the stock based on moves in the options market lately. That is because the Dec. 20, 2024 $17.50 Put had some of the highest ...

OEM parts are often more reliable and more expensive ... Editorial note: The name “Homefront” refers to the alliance between USA TODAY and Home Solutions that publishes review, comparison ...

On Monday, Agios Pharmaceuticals Inc (AGIO) stock saw a decline, ending the day at $44.43 which represents a decrease of $-1.18 or -2.59% from the prior close of $45.61. The stock opened at $45.61 and ...

Meridian Growth Fund highlighted stocks like Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), in the second quarter 2024 investor letter. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical ...

Leerink Partners downgraded Agios Pharmaceuticals (NASDAQ:AGIO) to Market Perform from Outperform on Friday, citing headwinds from Pfizer's (NYSE:PFE) recent decision to withdraw Oxbryta ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Agios Pharmaceuticals' Phase 3 ACTIVATE-KidsT study results reveal that mitapivat achieved a 28.1% transfusion reduction in children with PK deficiency compared to 11.8% with placebo. Secondary ...

Short interest in Agios Pharmaceuticals Inc (NASDAQ:AGIO) increased during the last reporting period, rising from 3.19M to 3.55M. This put 6.33% of the company's publicly available shares short.